VistaGen Therapeutics, Inc.VTGNNASDAQ
Loading
Year-over-year SG&A expense growth
5Y CAGR
-17.9%/yr
Long-term compound
Percentile
P67
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
1 qtr
Consecutive growthStable
| Period | Value |
|---|---|
| Q4 2025 | 24.91% |
| Q3 2025 | 0.59% |
| Q2 2025 | 2.27% |
| Q1 2025 | 5.53% |
| Q4 2024 | -3.48% |
| Q3 2024 | -8.15% |
| Q2 2024 | 10.85% |
| Q1 2024 | 9.63% |
| Q4 2023 | 17.18% |
| Q3 2023 | 7.69% |
| Q2 2023 | -5.61% |
| Q1 2023 | 2.03% |
| Q4 2022 | -16.48% |
| Q3 2022 | -22.74% |
| Q2 2022 | -3.41% |
| Q1 2022 | 59.11% |
| Q4 2021 | -3.20% |
| Q3 2021 | 33.60% |
| Q2 2021 | 36.21% |
| Q1 2021 | -16.39% |
| Q4 2020 | 66.69% |
| Q3 2020 | -8.70% |
| Q2 2020 | -2.25% |
| Q1 2020 | -32.91% |
| Q4 2019 | 85.08% |
| Q3 2019 | -40.00% |
| Q2 2019 | -42.52% |
| Q1 2019 | 81.47% |
| Q4 2018 | -15.66% |
| Q3 2018 | 48.09% |
| Q2 2018 | 1.81% |
| Q1 2018 | 45.71% |
| Q4 2017 | -56.79% |
| Q3 2017 | 96.31% |
| Q2 2017 | -80.13% |
| Q1 2017 | 207.63% |
| Q4 2016 | 29.05% |
| Q3 2016 | 34.52% |
| Q2 2016 | -86.07% |
| Q1 2016 | 490.31% |